Maxigesic IV® licensed in six new European nations

Thursday 30th July 2020

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) has signed an exclusive Maxigesic IV® licensing and supply agreement for Bulgaria, Cyprus, the Czech Republic, Hungary, Romania and Slovakia, countries with a combined population of more than 53 million*.

The agreement is with the Cyprus based multinational pharmaceutical company, Medochemie, which earlier this year signed a licensing agreement for Maxigesic IV® for Ukraine and the nine countries of the Commonwealth of Independent States.

AFT Pharmaceutical’s Managing Director Dr Hartley Atkinson says: “We are delighted to further strengthen our partnership with Medochemie. It is a strong, dynamic partner in this region and its business teams have an excellent understanding of their local markets.”

Maxigesic IV® regulatory approvals in the six European countries covered by this agreement are expected to conclude in the next few months, with sales then expected in the 2021calendar year.

Maxigesic IV® (Paracetamol 1000mg+ Ibuprofen 300mg solution for infusion) is an intravenous formulation developed as a line extension to Maxigesic tablets, for use post-operatively in hospitals when patients cannot take a medicine orally.

A major Phase 3 clinical trial conducted in the USA found that Maxigesic IV provided significantly better pain relief than either paracetamol (acetaminophen) IV or ibuprofen IV alone in the same doses.**

Following on from the registration of Maxigesic IV® in Australia and New Zealand in mid-2019, AFT has now licensed the medication in more than 90 countries. Meanwhile, the tablet form of Maxigesic has been licensed in more than 125 countries

References
* 2019 population. Source: Statista, 2020
**Daniels, S.E, Playne, R., Stanescu, I., Zhang, J., Gottlieb, I.J, Atkinson, H.C. (2019). Efficacy and safety of an intravenous acetaminophen/ibuprofen fixed-dose combination after bunionectomy: A randomized, double-blind, factorial, placebo- controlled trial. Clinical Therapeutics 41 (10): 1982-1995. Research sponsored by AFT Pharmaceuticals.

Source: AFT Pharmaceuticals (NZX.AFT, ASX.AFP)

Comments from our readers

No comments yet